ClinicalTrials.gg
RecruitingNCT05967611Updated Aug 1, 2023

Hip Abductor Function During Trendelenburg Test

An observational study in Weakness, Muscle, sponsored by Ahram Canadian University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-01.

Sponsored by Ahram Canadian University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 11 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
30
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Muscle Weakness with a site in Egypt — 4 open to participants now, 4 under way, none of them phase 3. Muscle Weakness · Egypt.

Started
2023
with 1 other
Observational
7 of 16
2 open now
Registered
10th of 16
by date
Lead sponsor
1 of 16
Ahram Canadian University

Among the 16 studies in Muscle Weakness with a site in Egypt, this one is one of 2 that started in 2023, is one of 7 observational ones, and was the 10th registered.

Muscle Weakness

478 studies on the registry are indexed under Muscle Weakness; 72 are open to participants now.

Browse Muscle Weakness studies →

Open to participants now

4 of the 16 studies in Muscle Weakness with a site in Egypt are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 52 Muscle Weakness studies recruiting now, 25 (48%) set no upper age limit and 20 (38%) stop at 75 or younger; 5 take children under 18; 18 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Muscle Weakness with a site in Egypt, or all of them as a file.
02

Study summary

This study will use electromyography and dynamometry to evaluate gluteal muscle activation during the Trendelenburg hip abduction test in different hip positions.

Read the detailed description

The Trendelenburg test is commonly used to assess hip abductor weakness. However, it is unclear which hip position during this test best isolates gluteal muscle function. This study will measure gluteus medius and minimus activation and hip abduction force in 30 healthy participants performing the Trendelenburg test. Different hip flexion, extension, adduction and abduction angles will be evaluated to determine which position optimally targets the gluteal muscles. Results may enhance utilization of the Trendelenburg test in clinical practice.

03

Conditions studied

  • Weakness, Muscle

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Healthy men and women aged 18-45 recruited from the local community.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults aged 18-45 years
  • No history of hip disorders

Exclusion criteria

Exclusion Criteria:

  • to EMG
  • Neurological or muscular disorders
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
30 participants (estimated)
Patient registry
No

Groups and cohorts

  • Healthy Adults

    At least 30 healthy adult participants aged 18-45 years performing the Trendelenburg hip abduction test

    Diagnostic Test: Trendelenburg hip abduction test

Interventions

  • Diagnostic testTrendelenburg hip abduction test

    The Trendelenburg test performed at different hip flexion, extension, adduction and abduction angles.

06

What researchers measure

Primary outcomes

  1. Gluteus Medius Activation

    Mean EMG activity of the gluteus medius during the Trendelenburg test at different hip positions. Measured bilaterally in microvolts (μV).

    Time frame: Baseline

Secondary outcomes

  1. Gluteus Minimus Activation during Trendelenburg Test

    Mean muscle activation amplitude (measured in microvolts, μV) of the gluteus minimus during the Trendelenburg hip abduction test across a range of hip flexion, extension, adduction and abduction angles from 0 to 45 degrees. Measured bilaterally using surface electromyography electrodes placed on the muscle belly of the gluteus minimus.

    Time frame: Baseline

  2. Hip Abduction Strength during Trendelenburg Test

    Maximum voluntary isometric hip abduction strength (measured in Newtons, N) during the Trendelenburg hip abduction test maneuver. Measured bilaterally at each combination of hip flexion, extension, adduction and abduction angles using a stabilized handheld dynamometer placed just proximal to the lateral femoral condyle.

    Time frame: Baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2023; primary completion for Dec 2023, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2023
First posted
Aug 1, 2023
StartEst.
Jul 25, 2023
Primary completionEst.
Dec 20, 2023
CompletionEst.
Dec 28, 2023
Last update
Aug 1, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05967611
Lead sponsor
Ahram Canadian University
Responsible party
Mohamed Magdy ElMeligie (Lecturer of Physical Therapy and Director of Electromyography Lab, Ahram Canadian University) — Principal investigator
First posted
Aug 1, 2023
Start date
Jul 25, 2023 (estimated)
Primary completion
Dec 20, 2023 (estimated)
Completion
Dec 28, 2023 (estimated)
Last update
Aug 1, 2023

Study contacts

Mohamed M ElMeligie, Ph.d
Contact
mohamed.elmeligie@acu.edu.eg
+201064442032
Amal Fawzy, Ph.d
study director · Faculty of Physical Therapy, Ahram Canadian University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion